NEXGEL implements 1-for-20 reverse split as NEXGEL stock faces Nasdaq test

Published on 10/16/2026 at 01:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Outstanding shares fell from 9,747,663 to 487,384 after the split. NEXGEL stock began split-adjusted Nasdaq trading on October 12, 2026.

Financial pressure follows restructuring

NEXGEL implemented a 1-for-20 reverse stock split on October 12, 2026.
NEXGEL reported USD 6.336 million in six-month revenue and a 34.2 percent gross margin for the period ended June 30, 2026.
NEXGEL reported a six-month net loss of USD 4.478 million for the period ended June 30, 2026.

NXGL, US65344E1073, Illustration mit AI erstellt.

NEXGEL (ISIN US65344E1073) implemented a 1-for-20 reverse stock split on October 12, 2026, as NEXGEL announced. The company said the action was intended to help regain compliance with Nasdaq's USD 1.00 minimum bid requirement, while warning that compliance could not be assured.

Three steps shaped the split

On August 17, 2026, NEXGEL reported second-quarter results for the period ended June 30, 2026, including six-month revenue of USD 6.336 million and a net loss of USD 4.478 million, according to MetaTrader. On September 23, 2026, stockholders approved authority for the reverse split at a special meeting, with the final ratio set at 1-for-20.

On October 12, 2026, the split became effective and split-adjusted trading began on the Nasdaq Capital Market under NXGL. The share count fell from 9,747,663 shares as of October 9, 2026, to approximately 487,384 before fractional-share adjustments, according to NEXGEL.

What does the split mean for finances?

The corporate action changes the number of shares and the per-share reference, but it does not repair the operating loss. For the six months ended June 30, 2026, revenue increased 11.4 percent from the prior-year period, while gross margin declined from 43.0 percent to 34.2 percent. MetaTrader attributed the margin pressure to lower initial margins on new biomaterial products, inventory write-offs, freight and royalty costs.

Liquidity remains central

NEXGEL's six-month operating cash flow was negative USD 2.701 million, while unrestricted cash stood at USD 0.5 million and convertible notes totaled USD 14.682 million. The figures make commercialization and financing important alongside the Nasdaq compliance effort. NEXGEL develops hydrogel products for healthcare and consumer applications, including wound care, medical diagnostics and cosmetic formulations.